These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38383367)

  • 1. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial.
    Kositz C; Vasileva H; Mohammed N; Achan J; Dabira ED; D'Alessandro U; Bradley J; Marks M
    Malar J; 2024 Feb; 23(1):54. PubMed ID: 38383367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia.
    Dabira ED; Soumare HM; Conteh B; Ceesay F; Ndiath MO; Bradley J; Mohammed N; Kandeh B; Smit MR; Slater H; Peeters Grietens K; Broekhuizen H; Bousema T; Drakeley C; Lindsay SW; Achan J; D'Alessandro U
    Lancet Infect Dis; 2022 Apr; 22(4):519-528. PubMed ID: 34919831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study.
    Slater HC; Foy BD; Kobylinski K; Chaccour C; Watson OJ; Hellewell J; Aljayyoussi G; Bousema T; Burrows J; D'Alessandro U; Alout H; Ter Kuile FO; Walker PGT; Ghani AC; Smit MR
    Lancet Infect Dis; 2020 Apr; 20(4):498-508. PubMed ID: 31948767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial.
    Dabira ED; Soumare HM; Lindsay SW; Conteh B; Ceesay F; Bradley J; Kositz C; Broekhuizen H; Kandeh B; Fehr AE; Nieto-Sanchez C; Ribera JM; Peeters Grietens K; Smit MR; Drakeley C; Bousema T; Achan J; D'Alessandro U
    JMIR Res Protoc; 2020 Nov; 9(11):e20904. PubMed ID: 33211022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.
    Smit MR; Ochomo EO; Aljayyoussi G; Kwambai TK; Abong'o BO; Chen T; Bousema T; Slater HC; Waterhouse D; Bayoh NM; Gimnig JE; Samuels AM; Desai MR; Phillips-Howard PA; Kariuki SK; Wang D; Ward SA; Ter Kuile FO
    Lancet Infect Dis; 2018 Jun; 18(6):615-626. PubMed ID: 29602751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia.
    Fehr A; Nieto-Sanchez C; Muela J; Jaiteh F; Ceesay O; Maneh E; Baldeh D; Achan J; Dabira E; Conteh B; Bunders-Aelen J; Smekens T; Broekhuizen H; D'Alessandro U; Peeters Grietens K
    Malar J; 2021 Apr; 20(1):198. PubMed ID: 33902611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.
    Hutchins H; Bradley J; Pretorius E; Teixeira da Silva E; Vasileva H; Jones RT; Ndiath MO; Dit Massire Soumare H; Mabey D; Nante EJ; Martins C; Logan JG; Slater H; Drakeley C; D'Alessandro U; Rodrigues A; Last AR
    BMJ Open; 2023 Jul; 13(7):e072347. PubMed ID: 37419638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
    McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM
    Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission.
    Morris U; Msellem MI; Mkali H; Islam A; Aydin-Schmidt B; Jovel I; Shija SJ; Khamis M; Ali SM; Hodzic L; Magnusson E; Poirot E; Bennett A; Sachs MC; Tarning J; Mårtensson A; Ali AS; Björkman A
    BMC Med; 2018 Dec; 16(1):215. PubMed ID: 30526588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed-method evaluation study of a targeted mass drug administration of long-acting anti-malarials among children aged 3 months to 15 years in the Bossangoa sub-prefecture, Ouham, Central African Republic, during the COVID-19 pandemic.
    Robinson E; Ouabo A; Rose L; van Braak F; Vyncke J; Wright R; Gray N; Sakama NS; Aboukar EJ; Fierte MM; Woinzoukou D; Ewers L; Serpande C; Stein S; Van Boetzelaer E; Kpahina OA; Sabe SC; Rao B; Kuehne A
    Malar J; 2024 May; 23(1):146. PubMed ID: 38750517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acceptability of mass administrations of anti-malarial drugs as part of targeted malaria elimination in villages along the Thai-Myanmar border.
    Kajeechiwa L; Thwin MM; Shee PW; Yee NL; Elvina E; Peapah P; Kyawt K; Oo PT; PoWah W; Min JR; Wiladphaingern J; von Seidlein L; Nosten S; Nosten F
    Malar J; 2016 Sep; 15(1):494. PubMed ID: 27677694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery strategies for malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years old in Malawi: a protocol for a cluster randomized trial.
    Gondwe T; Robberstad B; Mukaka M; Lange S; Blomberg B; Phiri K
    BMC Pediatr; 2018 Jul; 18(1):238. PubMed ID: 30029620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study.
    Mwesigwa J; Achan J; Affara M; Wathuo M; Worwui A; Mohammed NI; Kanuteh F; Prom A; Dierickx S; di Tanna GL; Nwakanma D; Bousema T; Drakeley C; Van Geertruyden JP; D'Alessandro U
    Clin Infect Dis; 2019 Jul; 69(2):278-286. PubMed ID: 30304511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia.
    Finn TP; Yukich JO; Bennett A; Porter TR; Lungu C; Hamainza B; Chizema Kawesha E; Conner RO; Silumbe K; Steketee RW; Miller JM; Keating J; Eisele TP
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):19-27. PubMed ID: 32618251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Non-Participation and Non-Adherence in Directly Observed Mass Drug Administration for Malaria in The Gambia.
    Dierickx S; Gryseels C; Mwesigwa J; O'Neill S; Bannister-Tyrell M; Ronse M; Jaiteh F; Gerrets R; D'Alessandro U; Grietens KP
    PLoS One; 2016; 11(2):e0148627. PubMed ID: 26866685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
    Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
    Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia.
    Eisele TP; Bennett A; Silumbe K; Finn TP; Porter TR; Chalwe V; Hamainza B; Moonga H; Kooma E; Chizema Kawesha E; Kamuliwo M; Yukich JO; Keating J; Schneider K; Conner RO; Earle D; Slutsker L; Steketee RW; Miller JM
    Am J Trop Med Hyg; 2020 Aug; 103(2_Suppl):7-18. PubMed ID: 32618247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya.
    Hill J; Ouma P; Oluoch S; Bruce J; Kariuki S; Desai M; Webster J
    Malar J; 2020 Nov; 19(1):433. PubMed ID: 33238999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.